Aptagen, LLC
DP7 (ID# 8845)
RNA
Human prion protein (PrP)
Protein
~1.7 µM (reported value)
Binding buffer (8 M urea, 20 mM sodium phosphate, 500 mM sodium chloride, pH 7.8)
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Kd= ~1.7µM (Human PrP)
Kd= 0.1-0.2 µM (Murine & hamster PrPs)
5'-rGprGprGprAprGprAprAprAprGprGprGprAprAprGprCprUprUprGprAprGprGprUprGprCprUprAprUprGprGprAprGprUprGprGprAprGprGprAprGprUprUprGprAprAprGprGprUprGprUprCprGprGprGprGprUprUprGprGprCprAprGprAprAprGprAprAprGprGprCprGprAprGprCprGprUprAprCprGprGprAprUprCprCprAprUprCp-3'
Mollasalehi N., Francois-Moutal L., Porciani D., Burke D.H., & Khanna M. (2022). Aptamers Targeting Hallmark Proteins of Neurodegeneration. Nucleic Acid Therapeutics, 32(4). https://doi.org/10.1089/nat.2021.0091
![](/wp-content/uploads/apta-sequence-abbr.png)
86
28288
889500
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Mollasalehi N., Francois-Moutal L., Porciani D., Burke D.H., & Khanna M. (2022). Aptamers Targeting Hallmark Proteins of Neurodegeneration. Nucleic Acid Therapeutics, 32(4). https://doi.org/10.1089/nat.2021.0091
Proske D., Gilch S., Wopfner F., Schätzl H.M., Winnacker E-L. Famulok M. (2002). Prion-Protein-Specific Aptamer Reduces PrPSc Formation. Chem BioChem, 3(8), 717-725 https://doi.org/10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.